Myriad Genetics (MYGN) Announces Proposed $100M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
November 8, 2023 4:10 PM ESTSALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the Company or Myriad Genetics), a leader in genetic testing and precision medicine, today announced that it plans to make a public offering of $100.0 million of shares of its common stock, par value $0.01 per share (common stock), in an underwritten registered public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional shares of its common stock. The offering is subject to market and other conditions, and there can be no... More
